Abstract:Background and purpose: Most of the pharmaceuticals target G-protein-coupled receptors (GPCRs) which can generally activate different signalling events. The aim of this study was to achieve functional selectivity of corticotropin-releasing factor receptor type 1 (CRF1) ligands. Experimental approach: We systematically substituted urocortin, a natural peptide agonist of CRF1, with bulky amino acids (benzoyl-phenylalanine, naphthylalanine) and determined the effect of the analogues on coupling of CRF1 to Gs-and G(i)-protein in human embryonic kidney cells, using receptor binding, [S-35]-GTPgS binding stimulation, and cAMP accumulation assays. Key results: Native ligands stimulated G(s) and G(i) activation through CRF1, resulting in stimulation and then inhibition of cAMP accumulation. Single replacements in urocortin at positions 6 -15 led, dependent on the position and nature of the substituent, to ligands that conserved G(s) activity, but were devoid of G(i) activity, only stimulating cAMP accumulation, and competitively antagonized the G(i) activation by sauvagine. In contrast, analogues with substitutions outside this sequence non-selectively activated G(s) and G(i), as urocortin did. Conclusions and implications: Modifications in a specific region, which we have called the signalling domain, in the polypeptide agonist urocortin resulted in analogues that behaved as agonists and, at the same time, antagonists for the activation of different G-proteins by CRF1. This finding implies significant differences between active conformations of the receptor when coupled to different G-proteins. A similar structural encoding of signalling information in other polypeptide hormone receptor ligands would result in a general concept for the development of signalling-selective drug candidates.

Receptor selectivity from minimal backbone modification of a polypeptide agonist

Single Hormone or Synthetic Agonist Induces Gs/Gi Coupling Selectivity of EP Receptors Via Distinct Binding Modes and Propagating Paths.

Recent Advances in the Drug Discovery and Development of Dualsteric/ Bitopic Activators of G Protein-Coupled Receptors.

Toward a Structural Understanding of Class B GPCR Peptide Binding and Activation.

Design of allosteric modulators that change GPCR G protein subtype selectivity

Highly biased agonism for GPCR ligands via nanobody tethering

G Protein-Coupled Estrogen Receptor (Gper) Agonist Dual Binding Mode Analyses Toward Understanding Of Its Activation Mechanism: A Comparative Homology Modeling Approach

Advances in Receptor Conformation Research: the Quest for Functionally Selective Conformations Focusing on the Β2-Adrenoceptor.

Conserved class B GPCR activation by a biased intracellular agonist

Backbone modification of a polypeptide drug alters duration of action in vivo

Achieving signalling selectivity of ligands for the corticotropin-releasing factor type 1 receptor by modifying the agonist's signalling domain.

Ligand recognition, unconventional activation, and G protein coupling of the prostaglandin E<sub>2</sub> receptor EP2 subtype

Small Molecule Allosteric Modulators of G-Protein-Coupled Receptors: Drug-Target Interactions.

Structural Understanding of Peptide-Bound G Protein-Coupled Receptors: Peptide-Target Interactions.

Constrained catecholamines gain β2AR selectivity through allosteric effects on pocket dynamics

Human somatostatin receptor specificity of backbone-cyclic analogues containing novel sulfur building units

State-specific Peptide Design Targeting G Protein-coupled Receptors

Molecular basis for the selective G protein signaling of somatostatin receptors

Molecular basis for allosteric agonism and G protein subtype selectivity of galanin receptors

G protein-coupled receptors (GPCRs): advances in structures, mechanisms, and drug discovery

Functional selectivity and dualsteric/bitopic GPCR targeting